Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab vedotin or B-CAP for older patients with newly diagnosed classical Hodgkin lymphoma
2013-003990-89Phase 2Completed
- Sponsor
- University of Cologne
- Start
- Feb 2015
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of brentuximab vedotin, doxorubicin, cyclophosphamide and prednisone in classical Hodgkin lymphoma (cHL) (2 arms), sponsored by University of Cologne. Primary endpoint: Objective response rate. Started Feb 2015; status: completed.
02
Drugs
brentuximab vedotindoxorubicincyclophosphamideprednisone
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on 2013-003990-89.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003990-89.